<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596399</url>
  </required_header>
  <id_info>
    <org_study_id>GV29259</org_study_id>
    <nct_id>NCT02596399</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers</brief_title>
  <official_title>A PHASE I, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF DSTA4637S IN HEALTHY VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study
      in healthy volunteers, enrolled at a single site in the United States to investigate the
      safety, tolerability, and pharmacokinetics of DSTA4637S.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2015</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with at least 1 Adverse Event (AE)</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of analytes of DSTA4637S in plasma and serum</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-therapeutic antibodies (ATA) to DSTA4637S</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>DSTA4637S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSTA4637S</intervention_name>
    <description>Participants will receive DSTA4637S intravenously on Day 1.</description>
    <arm_group_label>DSTA4637S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to DSTA4637S intravenously on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Able to comply with the study protocol, in the investigator's judgment

          -  Body mass index (BMI) between 18 and 32 kilogram per square meters (kg/m^2), inclusive

          -  In good health, determined by no clinically significant findings from medical history,
             12-lead electrocardiogram (ECG), and vital signs

          -  Clinical laboratory evaluations should be within the reference range for the test
             laboratory unless deemed not clinically significant by the investigator and Sponsor

          -  Willing to abstain from the use of drugs of abuse through completion of the study

          -  Willing to abstain from use of over the counter, herbal or prescription
             medications/products from 14 days prior to Day 1 through completion of the study,
             unless deemed acceptable by the investigator and Sponsor

          -  Agreeable to, and deemed able to (by the investigator), comply with requirements of
             the study, including the follow-up period

          -  Willing to abstain from consumption of alcohol-based products from 72 hours prior to
             Day 1 until Phase 1 unit check-out on Day 3 and for 72 hours prior to each follow-up
             visit

          -  For women of childbearing potential, agreement to remain abstinent (refrain from
             heterosexual intercourse) or use non-hormonal contraceptive methods that result in a
             failure rate of less than (&lt;) 1 percent (%) per year during the treatment period and
             for at least 85 days after the last dose of study drug

          -  For men, agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures and agreement to refrain from donating sperm, as defined in the
             study protocol

        Exclusion Criteria:

          -  Any diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that in the
             opinion of the investigator or Sponsor contraindicates the use of an investigational
             drug or that may affect the interpretation of the results or render the subject at
             high risk from treatment complications

          -  Use of tobacco, electronic cigarettes, personal vaporizer or electronic nicotine
             delivery systems (positive history within 3 months before initiation of dosing on Day
             1)

          -  Received any vaccine within 14 days prior to screening

          -  Pregnant or lactating, or intending to become pregnant within 3 months after screening

          -  Positive serum pregnancy test result at screening or Day &amp;#8722;1

          -  Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or
             intravenous antibiotics within 8 weeks before initiation of dosing

          -  Hospitalization within 4 weeks before initiation of dosing

          -  Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or
             human immunodeficiency virus (HIV) antibody

          -  History of significant drug abuse within 1 year prior to screening or use of soft
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs
             (such as cocaine, phencyclidine, and crack) within 1 year prior to screening

          -  Positive drug screen at screening or Day -1

          -  History of anaphylactic or hypersensitivity drug reaction, unless approved by the
             investigator and Sponsor

          -  Blood transfusion within 8 weeks prior to screening

          -  History of malignancy within 10 years of screening except completely excised basal
             cell carcinoma or squamous cell carcinoma of the skin

          -  Donation of plasma (greater than or equal to [&gt;=] 500 milliliter [mL]) within 7 days
             prior to study drug administration

          -  Donation or loss of whole blood (excluding the volume of blood that will be drawn
             during screening procedures) as follows: 50-499 mL of whole blood within 30 days or
             greater than (&gt;) 499 mL of whole blood within 56 days prior to study drug
             administration

          -  Hemoglobin &lt;128 gram per liter (g/L) (males) and &lt;115 g/L (females) and hematocrit
             &lt;0.37 L/L (males) and &lt;0.32 L/L (females) at screening

          -  Poor peripheral venous access

          -  History or presence of an abnormal ECG that is clinically significant in the
             investigator's opinion, including complete left bundle branch block, second- or
             third-degree heart block, evidence of prior myocardial infarction

          -  Exposure to any biological therapy or investigational biological agent within 90 days
             prior to the screening evaluation or have received any other investigational treatment
             30 days prior to the screening evaluation (or within 5 half-lives of the
             investigational product, whichever is greater)

          -  Any history of hypersensitivity or allergy to rifampin or other rifamycin analogs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International Clinical Pharmacology Center (EDS US Clinic)</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>DSTA4637S</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

